Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Payables (2016 - 2025)

Northwest Biotherapeutics' Payables history spans 16 years, with the latest figure at $40.3 million for Q4 2025.

  • Quarterly results put Payables at $40.3 million for Q4 2025, up 29.3% from a year ago — trailing twelve months through Dec 2025 was $40.3 million (up 29.3% YoY), and the annual figure for FY2025 was $40.3 million, up 29.3%.
  • Payables for Q4 2025 was $40.3 million at Northwest Biotherapeutics, roughly flat from $40.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $40.4 million in Q3 2025 to a low of $9.7 million in Q1 2021.
  • The 5-year median for Payables is $23.2 million (2023), against an average of $24.8 million.
  • The sharpest move saw Payables crashed 45.62% in 2023, then surged 119.59% in 2024.
  • Year by year, Payables stood at $14.1 million in 2021, then surged by 85.3% to $26.1 million in 2022, then crashed by 45.62% to $14.2 million in 2023, then surged by 119.59% to $31.2 million in 2024, then rose by 29.3% to $40.3 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $40.3 million, $40.4 million, and $40.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.